We're in an exciting new growth era at Lilly.

2018 was a momentous year for Lilly, with strong financial growth. We also concluded our strategic review of our Elanco Animal Health subsidiary, deciding to separate Elanco with an initial public offering in 2018 and complete divestiture in 2019. Lilly will now be focused on discovering and delivering new human medicines that change expectations for patients and drive results for shareholders.

2018 ISR Button Click for Full Report

2018 Financial Highlights

2018 ISR Financial Highlights Graphic